Guangdong Association Of Clinical Trials

This study tests a combination of the drug serplulimab plus chemotherapy in people whose lung cancer has changed from one type (EGFR-mutated non-small cell) to another (small cell) after prior treatment. About 66 adults aged 18-75 in China will receive the treatment to see if it …

This study is for people with advanced EGFR-mutated non-small cell lung cancer whose cancer still shows signs of activity (ctDNA positive) after initial treatment with osimertinib. Researchers want to see if adding a second drug, sacituzumab tirumotecan, can improve outcomes. Abo…

This study is for people with stage II to IIIB non-small cell lung cancer who had surgery after initial chemotherapy plus immunotherapy but still had some cancer cells left. The trial uses a blood test to look for tiny bits of cancer DNA (called MRD) to decide if more immunothera…

This study tests a combination of two drugs (IBI351 and cetuximab β) in people with advanced non-small cell lung cancer that has a specific genetic change called KRAS G12C. The goal is to see if the treatment shrinks tumors and controls the disease. About 48 adults who have not h…